https://scholars.lib.ntu.edu.tw/handle/123456789/524396
標題: | Duration of dual antiplatelet therapy following percutaneous coronary intervention on re-hospitalization for acute coronary syndrome | 作者: | Chen S.-C. FEI-YUAN HSIAO CHII-MING LEE Hsu W.W.Y. Gau C.-S. |
關鍵字: | Acute coronary syndrome (ACS); Clopidogrel; Drug eluting stent (DES); Dual antiplatelet therapy; Percutaneous coronary intervention (PCI) | 公開日期: | 2014 | 出版社: | BioMed Central Ltd. | 卷: | 14 | 來源出版物: | BMC Cardiovascular Disorders | 摘要: | Background: The optimal duration of dual antiplatelet therapy after percutaneous coronary intervention (PCI) remains uncertain. The objective of this study was to examine the association between duration of dual antiplatelet therapy and re-hospitalization for acute coronary syndrome (ACS) in ACS patients who underwent PCI.Methods: We identified 975 newly diagnosed ACS patients who underwent PCI between July, 2007 and June, 2009, at a medical center in Taiwan. Cox proportional hazard models were used to examine the association between duration of dual antiplatelet therapy (9?months, 12?months and 15?months) and risks of re-hospitalization for ACS.Results: At a mean follow-up of 2.3?years, we found that use of clopidogrel for ? 12?months was associated with a decreased risk of re-hospitalization for ACS (adjusted HR 0.59, 95% CI 0.36-0.95; p = 0.03). However, use of clopidogrel for ? 15?months was not associated with a decreased risk of re-hospitalization for ACS (adjusted HR 0.57, 95% CI 0.29-1.13; p = 0.11). Similar results were found in patients who implanted drug-eluting stents (DES), for whom at least 12?months of clopidogrel therapy is especially critical.Conclusion: The benefit of ? 12?months of clopidogrel use in reducing the risk of re-hospitalization for ACS was significant among ACS patients who underwent PCI and was especially critical for those who implanted DES. ? 2014 Chen et al.; licensee BioMed Central Ltd. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84898596475&doi=10.1186%2f1471-2261-14-21&partnerID=40&md5=f3b32a54c2bc629954ab984f62158811 https://scholars.lib.ntu.edu.tw/handle/123456789/524396 |
ISSN: | 1471-2261 | DOI: | 10.1186/1471-2261-14-21 | SDG/關鍵字: | acetylsalicylic acid; angiotensin receptor antagonist; antilipemic agent; beta adrenergic receptor blocking agent; calcium channel blocking agent; clopidogrel; cyclooxygenase 2 inhibitor; digoxin; dipeptidyl carboxypeptidase inhibitor; diuretic agent; everolimus; nitrate; nonsteroid antiinflammatory agent; paclitaxel; rapamycin; zotarolimus; acute coronary syndrome; adult; anticoagulant therapy; article; cardiovascular parameters; cohort analysis; comorbidity; controlled study; coronary artery obstruction; correlation analysis; drug eluting stent; drug withdrawal; endothelial progenitor cell; female; follow up; hospital readmission; human; hypertension; major clinical study; male; non ST segment elevation myocardial infarction; percutaneous coronary intervention; priority journal; retrospective study; risk assessment; risk factor; Taiwan; treatment duration; vascular disease; Acute Coronary Syndrome; Aged; Aspirin; Chi-Square Distribution; Drug Administration Schedule; Drug Therapy, Combination; Drug-Eluting Stents; Female; Humans; Male; Middle Aged; Multivariate Analysis; Patient Readmission; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Proportional Hazards Models; Retrospective Studies; Risk Factors; Taiwan; Ticlopidine; Time Factors; Treatment Outcome |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。